Eisai Co., Ltd.｜A Human Health Care Company

• Human Capital Report 2024

  Learn more

  

  Human Capital Report 2024

  Learn more

• Value Creation Report 2024

  Learn more

  

  Value Creation Report 2024

  Learn more

• World Alzheimer’s Month ー Life Goes On 2024

  A documentary video portraying the daily life of people living with dementia (in Japanese)

  Learn more

  

  World Alzheimer’s Month ー Life Goes On 2024

  A documentary video portraying the daily life of people living with dementia (in Japanese)

  Learn more

• "Diversity, Equity and Inclusion" Page Renewal

  Introducing Eisai DE&I: Now and the Future

  Learn more

  

  "Diversity, Equity and Inclusion" Page Renewal

  Introducing Eisai DE&I: Now and the Future

  Learn more

• Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets

  Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships

  Learn more

  

  Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets

  Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships

  Learn more

• 

  FY2024 Second Quarter Financial Results Presentation

• 

  Recent hhc Activities “Let‘s Learn More about Cancer Patients”

• 

  Overview of Eisai's Initiatives for Dementia

• 

  Eisai India’s Initiatives for Eliminating Lymphatic Filariasis

• News Release
• Latest News
• Information

• December 23, 2024

  Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

• December 11, 2024

  “URECE®” (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA

• December 5, 2024

  “LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico

• November 29, 2024

  Eisai Announces Completion of Cancellation of Treasury SharesCancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act

• November 28, 2024

  “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea

View All

• December 23, 2024

  About Eisai “Corporate Governance Report”

• November 21, 2024

  Recent hhc Activities “Online Exchange Program between Lymphatic Filariasis Patients from Ommi Village, India, and Eisai Employees ー Feeling the Unspoken Emotions of Patients”

• November 11, 2024

  IR “Second Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2025 (Material, Webcast)”

• November 8, 2024

  IR “Second Quarter Financial Report for the Fiscal Year Ending March 31, 2025”

• September 30, 2024

  IR “Annual Securities Report (Summary)”

View All

• October 3, 2024

  EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024

• June 21, 2024

  Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”

• June 3, 2024

  The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”

• April 8, 2024

  Eisai Participates in Kakamigahara City’s SDGs Promotion Program through its Activities Including Waste Recycling at the Kawashima Plant

• October 13, 2023

  Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness

View All

Sustainability

32 countries 2.38 billion tablets

Number of countries supplied with lymphatic filariasis treatment and volume supplied (as of October 2024)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

• Message from Top Management
• Eisai's Sustainability
• Sustainability Management
• Initiatives for Improving Access to Medicines
• Environmental
• Society
• Governance
• ESG Data & Report

Sustainability TOP

• 

  Improving Access to Medicines TOP

• 

  Initiatives for Elimination of Neglected Tropical Diseases

• 

  Initiatives for Improving Access to Medicines for Non-communicable Diseases

• 

  Research & Development for Improving Access to Medicines

• 

This website uses cookies to enhance your browsing experience. By using this site, you agree to our use of cookies. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Read more

close